Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 1/20 | 0.50 |
| ▸ | CYP46A1 | Q9Y6A2 | 5/20 | 0.36 |
| ▸ | PGR | P06401 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.36 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.36 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.36 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.36 |
| ▸ | CCKBR | P32239 | 1/20 | 0.36 |
| ▸ | PPARG | P37231 | 1/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.36 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.36 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL524308 | 1.00 | AR (0.50) | ARCYP46A1PGRMAPK1NR1I2 | |
| SCHEMBL30436667 | 1.00 | AR (0.50) | ARCYP46A1PGRMAPK1NR1I2 | |
| SCHEMBL1703087 | 0.92 | AR (0.47) | ARCYP46A1PGRMAPK1NR1I2 | |
| SCHEMBL1703090 | 0.92 | AR (0.47) | ARCYP46A1PGRMAPK1NR1I2 | |
| SCHEMBL9941766 | 0.86 | AR (0.52) | ARCYP46A1PGRMAPK1NR1I2 | |
| SCHEMBL9941767 | 0.86 | AR (0.52) | ARCYP46A1PGRMAPK1NR1I2 | |
| SCHEMBL28442385 | 0.86 | AR (0.37) | ARCYP46A1PGRSMN1; SMN2CYP3A4 | |
| SCHEMBL28441826 | 0.86 | AR (0.37) | ARCYP46A1PGRSMN1; SMN2CYP3A4 | |
| SCHEMBL1702851 | 0.85 | AR (0.45) | ARSMN1; SMN2ALDH1A1 | |
| SCHEMBL1702847 | 0.85 | AR (0.45) | ARSMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 121 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108947855-B | Synthesis method of efavirenz key intermediate | 江苏沙星化工有限公司 | 2021-10-22 | — | — | CN | claimed |
| EP-3548469-B1 | METHOD FOR THE MANUFACTURE OF EFAVIRENZ | UNIV NELSON MANDELA METROPOLITAN (ZA) | 2020-08-26 | — | — | EP | claimed |
| US-10689353-B2 | Method for the manufacture of Efavirenz | NELSON MANDELA METROPOLITAN UNIVERSITY (ZA) | 2020-06-23 | — | — | US | claimed |
| US-20200062722-A1 | Method For The Manufacture of Efavirenz | NELSON MANDELA METROPOLITAN UNIVERSITY (ZA) | 2020-02-27 | — | — | US | claimed |
| EP-3548469-A1 | METHOD FOR THE MANUFACTURE OF EFAVIRENZ | Nelson Mandela Metropolitan University (ZA) | 2019-10-09 | — | — | EP | claimed |
| WO-2018154414-A1 | METHOD FOR THE MANUFACTURE OF EFAVIRENZ | NELSON MANDELA METROPOLITAN UNIVERSITY (ZA) | 2018-08-30 | — | — | WO | claimed |
| CN-115819256-A | Purification method of efavirenz intermediate | 上海迪赛诺生物医药有限公司 | 2023-03-21 | — | — | CN | disclosed |
| CN-108947855-B | Synthesis method of efavirenz key intermediate | 江苏沙星化工有限公司 | 2021-10-22 | — | — | CN | disclosed |
| EP-3548469-B1 | METHOD FOR THE MANUFACTURE OF EFAVIRENZ | UNIV NELSON MANDELA METROPOLITAN (ZA) | 2020-08-26 | — | — | EP | disclosed |
| US-10689353-B2 | Method for the manufacture of Efavirenz | NELSON MANDELA METROPOLITAN UNIVERSITY (ZA) | 2020-06-23 | — | — | US | disclosed |
| US-10689353-B2 | Method for the manufacture of Efavirenz | NELSON MANDELA METROPOLITAN UNIVERSITY (ZA) | 2020-06-23 | — | — | US | disclosed |
| US-20200062722-A1 | Method For The Manufacture of Efavirenz | NELSON MANDELA METROPOLITAN UNIVERSITY (ZA) | 2020-02-27 | — | — | US | disclosed |
| US-20200062722-A1 | Method For The Manufacture of Efavirenz | NELSON MANDELA METROPOLITAN UNIVERSITY (ZA) | 2020-02-27 | — | — | US | disclosed |
| US-6040480-A | PREPARING 2-(1,1,1-TRIFLUORO-2-HYDROXY-4-CYCLOPROPYL-BUT-3-YN-2-YL),4-CHLOROANILINE; CYCLIZATION; HUMAN IMMUNODEFICIENCY VIRUS (HIV) REVERSE TRANSCRIPTASE INHIBITOR NONTOXIC MAATERIALS; NONCHROMAGRAPHIC PURIFICATION | DU PONT PHARMACEUTICALS COMPANY (US) | 2000-03-21 | — | — | US | disclosed |
| US-6028237-A | Synthesis of cyclopropylacetylene | DUPONT PHARMACEUTICALS COMPANY (US) | 2000-02-22 | — | — | US | disclosed |
| EP-0973755-A1 | ASYMMETRIC SYNTHESIS OF BENZOXAZINONES VIA NEW INTERMEDIATES | Du Pont Pharmaceuticals Company (US) | 2000-01-26 | — | — | EP | disclosed |
| US-5932726-A | VIRICIDE, ENZYME INHIBITOR; 6-CHLORO-4-CYCLOPROPYLETHYNYL4-TRIFLUOROMETHYL-1,4-DIHYDRO2H-3 ,1-BENZOXAZIN-2-ONE | DUPONT PHARMACEUTICALS COMPANY (US) | 1999-08-03 | — | — | US | disclosed |
| US-5925789-A | MULTISTAGE PROCESS WITH AMINATION, DEHYDRATION AND STIRRING TO GIVE AN INTERMEDIATE IN THE SYNTHESIS OF 6-CHLORO-4-CYCLO PROPYLETHYNYL-4-TRIFLUOROMETHYL-1,4-2H-3,1-BENZOXAZINE-2-ONE AS AN INHIBITOR OF HIV REVERSE TRANSCRIPTASE | DUPONT PHARMACEUTICALS COMPANY (US) | 1999-07-20 | — | — | US | disclosed |
| WO-1998045278-A1 | ASYMMETRIC SYNTHESIS OF BENZOXAZINONES VIA NEW INTERMEDIATES | DU PONT PHARMACEUTICALS COMPANY (US) | 1998-10-15 | — | — | WO | disclosed |
| WO-1998027034-A1 | AN IMPROVED SYNTHESIS OF CYCLOPROPYLACETYLENE | DU PONT PHARMACEUTICALS COMPANY (US) | 1998-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10689353-B2 | Method for the manufacture of Efavirenz | CYP2F1, CYP2D6, CYP3A4 | AR 2908/4885CYP46A1 271/4885PGR 4533/4885 |
| US-20200062722-A1 | Method For The Manufacture of Efavirenz | CYP2F1, CYP2D6, CYP3A4 | AR 2908/4885CYP46A1 271/4885PGR 4533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.